pharmaceuticals
pharmaceuticals Articles
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
Published:
Last Updated:
Last week, a few biotech companies made absolutely massive runs, while others had serious falls.
Published:
Last Updated:
The health care sector may have sold off a fair amount since this past summer, but there is some M&A action between giants in the sector that has potential to heat it back up.
Published:
Last Updated:
Wave Life Sciences has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 5 million shares in the...
Published:
Last Updated:
Shire and Dyax announced Monday morning that former will acquire latter for almost $6 billion.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions coming up in the month of November.
Published:
Last Updated:
Last week, a few biotech companies made absolutely massive runs, and some had serious falls.
Published:
Last Updated:
Voyager Therapeutics intends to offer roughly 4.7 million shares within the range of $15 to $17 apiece in an IPO valued up to more than $91 million.
Published:
Last Updated:
Mylan reported better-than-expected third-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
AbbVie reported better-than-expected third-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
Mylan is scheduled to release its third-quarter financial results before the markets open on Friday.
Published:
AbbVie is expected to report its third-quarter financial results before the markets open on Friday.
Published:
Kura Oncology is offering $60 million worth of shares in its initial public offering at an expected $16 per share.
Published:
Allergan has issued a press release that confirms some of the rumors floating in the market that it has been approached by Pfizer.
Published:
24/7 Wall St. screened the RBC specialty pharmaceutical universe and found six companies rated Outperform with over 100% upside to the firm's price target.
Published: